Press Release
Clalit and Carmel Medical Center, signed a contract with Montfort to develop an innovative visual acuity test for Multiple Sclerosis patients.
Montfort (Mon4t), a company specializing in the development of digital medical solutions, announced today (March 18th, 2025) the signing of a contract with Clalit and Carmel Medical Center to develop a digital visual acuity test. The new test will complement Montfort’s existing test suite, which is already being implemented among multiple sclerosis patients, and provides a comprehensive set of neurological tests to monitor symptoms of this disease.
Dr. Danny Golan, Director of the Multiple Sclerosis and Neuroimmunology Clinic at Carmel Medical Center, part of the Clalit Group, says:
“With the help of Montfort’s digital tools, it is possible to obtain a more quantitative and continuous tracking of the patients’ condition. Adding visual acuity testing to the existing system will make the monitoring of multiple sclerosis patients even more comprehensive, and will help in adapting personal treatment for each patient and identifying worsening of their condition.”
Tens of thousands of Israelis and many millions around the world are required to have repeated and recurring visual acuity tests to monitor eye function under a variety of visual impairments and neurological diseases,” noted Dr. Alavit Wolf, Director of the Pediatric Ophthalmology Unit and Medical Director of the Innovation Center at Carmel Medical Center. “An accessible visual acuity test will allow doctors to identify changes at an early stage and adjust treatment. The new development will contribute greatly to making monitoring and treatment accessible for patients.”
Prof. Ran Blitzer, Head of Innovation at Clalit, and Dr. Sharon Kama, Director of the Innovation Center at Carmel Medical Center, note that: “We are pleased to take part in this groundbreaking medical-technological project. Promoting digital health is a key strategic goal of Clalit, and the new test will allow us to continue to lead in the field of innovation, while providing high-quality, personalized medical solutions to patients.”
“We are proud to expand our collaboration with Carmel Medical Center and Clalit,” added Dr. Ziv Yekutieli, CEO of Montfort. “The development of the visual acuity test will allow us to provide multiple sclerosis patients with a complete solution, offering simple self-monitoring from home. This is another important step towards improving the quality of life of patients and reducing the need for frequent visits to the clinic.”
The new test will be developed in close collaboration between the medical teams, researchers and developers of Montfort, Carmel Medical Center and Clalit, with the aim of making the monitoring process accessible and easier for multiple sclerosis patients. The completion of the test is expected to strengthen Montfort’s portfolio of digital solutions, increase the coverage it provides for clinical trials of new MS drugs, and provide a rapid medical response to all patients suffering from a worsening of their condition.
